Phase 4 N=21 Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=67 Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
HIV Infection · Hepatitis C Infection
Primary: Percentage of Participants With Complete Early Virologic Response (cEVR) — 38.8 percentage of participants
Phase 2 N=30 Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
HIV-HCV
Primary: The Percentage of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 90; 80 Percentage of subjects
Phase 2 N=29 Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients
Hepatitis C · HIV Infections
Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants
Phase 4 N=18 HCV-HIV Co-infected Patient Cohort in Thailand
Hepatitis C Infection · HIV
Primary: Number of Participants With Sustained Virological Response 6 Months After Treatment Discontinuation — 10 Participants
Phase 2 N=36 Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
Hepatitis C · HIV Infections
Primary: Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response — 8 participants with post treatment svr
Phase 3 N=262 Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
HIV Infections · Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24) — 34.8; 25.4 percentage of participants
Phase 3 N=203 A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
Hepatitis C
Primary: Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Treatment-naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) — 96.4 Percentage…
Phase 2 N=255 Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)
HIV Infections · Hepatitis C · Liver Disease
Primary: Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS) — 0; 0 Metavir units per one year (52 weeks) — p=0.58
Phase 4 N=87 Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
Cardiovascular Diseases · Hepatitis C · Hiv
Primary: Change in Cardiovascular Disease Risk From Baseline to After Functional Cure of Hepatitis C, as Measured by High-sensitivity C-reactive Protein — 0.6; 0 mg/L
N/A N=68 Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection
HIV · Hepatitis C, Chronic
Primary: Number of Participants Linked to Care — 8; 16 Participants — p=0.036
Phase 4 N=25 HCV Positive Heart Donors
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
Phase 2 N=62 Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
Hepatitis C · HIV Infections
Primary: Proportion of Subjects Achieving Undetectable HCV RNA at Week 12 — 6; 2; 14; 2 participants
Phase 4 N=68 Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
HIV · Hepatitis C · Cirrhosis
Primary: Number of Participants With Sustained Virologic Response (SVR) — 38; 25 Participants
Phase 4 N=15 Hepatitis C Virus(HCV) Heart and Lung Study
Hepatitis C, Chronic · Heart Failure · Pulmonary Disease, Chronic Obstructive
Primary: Number of Subjects Who Completed 24 Weeks of Therapy — 0; 1 Participants
Phase 2 N=50 Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV
Hepatitis C · HIV
Primary: Percentage of Participants With Achieved SVR12 (HCV RNA <LLOQ 12 Weeks After Completion of Treatment) — 97; 100 percentage of participants
Phase 4 N=180 Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response (SVR) — 23.8; 36.5 percentage of participants — p=0.0536
N/A N=198 Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
HCV · Buprenorphine · PreP
Primary: Hepatitis C Virus (HCV) Cure (Sustained Virologic Response) — 158 Participants
N/A N=529 The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID
Hepatitis C · Drug Users · Harm Reduction
Primary: Percentage of HCV Infected Paticipants Whom Result of the Test Was Delivered to — 101 Participants
Phase 4 N=6 Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C
Hepatitis C, Chronic · HIV
Primary: Proportion of Subjects With Sustained Virologic Response (SVR12) — 3; 2 Participants
Phase 2 N=548 Staged Phase I/II Hepatitis C Prophylactic Vaccine
Hepatitis C
Primary: Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months — 14; 14 Participants — p=0.317
Phase 4 N=137 A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
HIV Coinfection
Primary: Percentage of Participants With Grade 3 and Grade 4 Alanine Aminotransferase (ALT) Abnormalities at Week 48 — 1.4; 1.5 Percentage of participants — p=0.4598
Phase 3 N=107 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 95.3 percentage of participants
Phase 2 N=57 Dutch Acute HCV in HIV Study (DAHHS)
Hepatitis C · Human Immunodeficiency Virus
Primary: Sustained Viral Response(SVR) 12 Weeks of Follow up After the End of All Therapy for the Rapid Viral Response at Week 4(RVR4) Population. — 41 participants
Phase 4 N=80 Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
Hepatitis C, Chronic · HIV Infection
Primary: Rates of Grade 2 and Higher Alanine Aminotransferase (ALT) Elevations — 24; 30 Participants
Phase 2 N=45 Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
Hepatitis C Infection · HIV Infection
Primary: Percentage of Participants With Sustained Virologic Response at 12 Weeks Post Treatment Discontinuation (SVR12) — 84.4 percentage of participants
Phase 1 N=17 MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)
Hepatitis C
Primary: Number of Participants With Vaccine-related Clinical (Systemic and Injection-site), and Laboratory Adverse Events (AE) — 5; 1; 3; 1 Participants
Phase 4 N=34 Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs
Hepatitis C
Primary: sCD14 (ng/mL) — 1986; 1918; 1542; 2060 ng/mL — p=0.07
Phase 3 N=275 A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Chronic Hepatitis C · Human Immunodeficiency Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 89.5; 84.8; 84.0; 90.9 percentage of participants
Phase 3 N=301 Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
Hepatitis C, Genotype 1
Primary: Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) — 75; 71.8; 71.7; 73.3 Percentage of participants